This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Blood Stream Infection Testing industry.
What is the current market size of the blood stream infection testing industry, and what growth rate is it expected to achieve?
The blood stream infection testing market size has grown rapidly in recent years. It will grow from $7.59 billion in 2024 to $8.49 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to the rising incidence of hospital-acquired infections, growing prevalence of antimicrobial resistance, increasing aging population, increasing healthcare expenditure, and rising prevalence of chronic diseases.
The blood stream infection testing market size is expected to see rapid growth in the next few years. It will grow to $13.19 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic tests, growing adoption of molecular diagnostics, rising focus on personalized medicine, government initiatives for infection control, and rising prevalence of multi-drug-resistant pathogens. Major trends in the forecast period include the growing use of AI in diagnostic tools, integration of telemedicine with diagnostic services, rising demand for home-based testing kits, development of multiplex diagnostic platforms, and growing partnerships between diagnostic companies and hospitals.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20514&type=smp
What are the major drivers contributing to the growth of the blood stream infection testing market?
The increasing prevalence of infectious diseases is expected to propel the growth of the blood stream infection testing market going forward. Infectious diseases are defined as illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. Infectious disease rates are on the rise owing to several factors such as increased global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Bloodstream infection testing is essential in infectious diseases for diagnosing and identifying pathogens causing sepsis and other severe infections, enabling targeted and effective treatment. For instance, in December 2023, according to the latest World Malaria report published by the World Health Organization (WHO), a Switzerland-based United Nations agency, there were 249 million cases of malaria in 2022 compared to 244 million cases in 2021. The estimated number of malaria deaths stood at 608,000 in 2022 compared to 610,000 in 2021. Therefore, the increasing prevalence of infectious diseases is driving the blood stream infection testing market.
What are the major market segments driving the growth of the blood stream infection testing industry?
The blood stream infection testing market covered in this report is segmented –
1) By Product Type: Instruments, Reagents And Consumables, Software And Services
2) By Sample Type: Whole Blood, Blood Culture
3) By Technology: Polymerase Chain Reaction (PCR), Mass Spectroscopy, In Situ Hybridization, Other Technologies
4) By End-User: Hospitals And Diagnostic Centers, Laboratory Service Providers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Instruments: Blood Culture Systems, Automated Microbial Identification Systems, Molecular Diagnostic Instruments
2) By Reagents and Consumables: Blood Culture Media, Antimicrobial Susceptibility Testing Reagents, Nucleic Acid Extraction Kits
3) By Software and Services: Laboratory Information Management Systems (LIMS), Data Analysis Software, Maintenance And Support Services
View The Full Market Report:
What are the key trends shaping the blood stream infection testing market in the forecast period?
Major companies operating in the bloodstream infection testing market are focusing on developing innovative products, such as blood testing cartridges, to sustain their position in the market. Blood testing cartridges are disposable devices used for analyzing blood samples in diagnostic tests. They contain preloaded reagents and integrated sensors or microfluidic channels that facilitate the detection of specific biomarkers, pathogens, or conditions from a small blood sample. For instance, in August 2022, Immunexpress Pty Ltd., an Australia-based molecular diagnostics company, launched the SeptiCyte RAPID cartridges. These cartridges use undiluted ethylenediaminetetraacetic acid (EDTA) blood as a validated sample type, demonstrated to have a high correlation with other blood collection methods through a multi-site European study. This advancement improves the accuracy and efficiency of sepsis diagnosis, enabling wider and quicker clinical adoption and potentially transforming patient care while lowering healthcare costs.
Who are the key market players contributing to the growth of the blood stream infection testing industry?
Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.
Which regions are leading the growth of the blood stream infection testing market globally?
North America was the largest region in the blood stream infection testing market in 2024. The regions covered in the blood stream infection testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Blood Stream Infection Testing Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20514
Need Customized Data On Blood Stream Infection Testing Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20514&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
